Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer
Matulonis, U.A., Wulf, G.M., Barry, W.T., Birrer, M., Westin, S.N., Farooq, S., Bell-McGuinn, K.M., Obermayer, E., Whalen, C., Spagnoletti, T., Luo, W., Liu, H., Hok, R.C., Aghajanian, C., Solit, D.B.Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw672
Date:
December, 2016
File:
PDF, 428 KB
english, 2016
File converter
More search results
More benefits 
